Mirte P. Van Der Heijden
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.
Journal: Oncoimmunology
Published: April 10, 2026
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 01, 2025
Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 14, 2025
Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 14, 2025
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
Journal: Cancer immunology, immunotherapy : CII
Published: January 28, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2025
Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Journal: Nature communications
Published: December 20, 2024
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.
Journal: Molecular therapy. Oncology
Published: November 29, 2024
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Journal: Cancer gene therapy
Published: November 27, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 19, 2024
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Journal: Nature communications
Published: May 21, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 10, 2023
Last Updated: 09/26/2026